Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review

por D’Souza, Ryan S., Her, Yeng F., Jin, Max Y., Morsi, Mahmoud, Abd-Elsayed, Alaa
Publicado 2022

Evaluation of Laminated Composite Beam Theory Accuracy

por Lyu, Yu-Ting, Hung, Tsung-Pin, Ay, Her-Chang, Tsai, Hsiu-An, Chiang, Yih-Cherng
Publicado 2022

Improved Electrical Characteristics of AlGaN/GaN High-Electron-Mobility Transistor with Al(2)O(3)/ZrO(2) Stacked Gate Dielectrics

por Huang, Cheng-Yu, Mazumder, Soumen, Lin, Pu-Chou, Lee, Kuan-Wei, Wang, Yeong-Her
Publicado 2022

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

por Eskens, F A L M, Mom, C H, Planting, A S T, Gietema, J A, Amelsberg, A, Huisman, H, van Doorn, L, Burger, H, Stopfer, P, Verweij, J, de Vries, E G E
Publicado 2008

La recherche de la surexpression de la protéine et l'amplification du gène HER2 dans le cancer de l'estomac par immunohistochimie et Hybridation in Situ: expérience du CHU HASSAN II de Fès

por El Fatemi, Hinde, Hammas, Nawal, Idrissi, Karima, Mellas, Nawfel, Bennani, Amal, Amarti, Afaf, Cayre, Anne, Penault-llorca, Frederique, Mesbahi, Omar
Publicado 2012

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

por Masuda, Norikazu, Ohtani, Shoichiro, Takano, Toshimi, Inoue, Kenichi, Suzuki, Eiji, Nakamura, Rikiya, Bando, Hiroko, Ito, Yoshinori, Ishida, Kazushige, Yamanaka, Takashi, Kuroi, Katsumasa, Yasojima, Hiroyuki, Kasai, Hiroi, Takasuka, Tsuyoshi, Sakurai, Takaki, Kataoka, Tatsuki R., Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Publicado 2020

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

por Decker, Thomas, Söling, Ulrike, Hahn, Antje, Maintz, Christoph, Kurbacher, Christian Martin, Vehling-Kaiser, Ursula, Sent, Dagmar, Klare, Peter, Hagen, Volker, Chiabudini, Marco, Falkenstein, Julia, Indorf, Martin, Runkel, Eva, Potthoff, Karin
Publicado 2020

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician?...

por Omarini, Claudia, Piacentini, Federico, Sperduti, Isabella, Barbolini, Monica, Isca, Chrystel, Toss, Angela, Cortesi, Laura, Barbieri, Elena, Dominici, Massimo, Moscetti, Luca
Publicado 2020

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

por Berger, Frédérique, Marce, Margaux, Delaloge, Suzette, Hardy-Bessard, Anne-Claire, Bachelot, Thomas, Bièche, Ivan, Pradines, Anne, De La Motte Rouge, Thibault, Canon, Jean-Luc, André, Fabrice, Arnould, Laurent, Clatot, Florian, Lemonnier, Jérôme, Marques, Sandrine, Bidard, François-Clement
Publicado 2022

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]

por Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.
Publicado 2021

Wo kommen wir her? Wo stehen wir? Wo gehen wir hin?: Präsidentenrede zur 92. ...

por Plontke, Stefan K.
Publicado 2022

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

por Schneeweiss, Andreas, Ettl, Johannes, Lüftner, Diana, Beckmann, Matthias W., Belleville, Erik, Fasching, Peter A., Fehm, Tanja N., Geberth, Matthias, Häberle, Lothar, Hadji, Peyman, Hartkopf, Andreas D., Hielscher, Carsten, Huober, Jens, Ruckhäberle, Eugen, Janni, Wolfgang, Kolberg, Hans Christian, Kurbacher, Christian M., Klein, Evelyn, Lux, Michael P., Müller, Volkmar, Nabieva, Naiba, Overkamp, Friedrich, Tesch, Hans, Laakmann, Elena, Taran, Florin-Andrei, Seitz, Julia, Thomssen, Christoph, Untch, Michael, Wimberger, Pauline, Wuerstlein, Rachel, Volz, Bernhard, Wallwiener, Diethelm, Wallwiener, Markus, Brucker, Sara Y.
Publicado 2020

Identification of regulatory variants of carboxylesterase 1 (CES1): A proof‐of‐concept study for the application of the Allele‐Specific Protein Expression (ASPE) assay in identifyi...

por Her, Lucy, Shi, Jian, Wang, Xinwen, He, Bing, Smith, Logan S., Jiang, Hui, Zhu, Hao‐Jie
Publicado 2022

Multi-Level Resistive Al/Ga(2)O(3)/ITO Switching Devices with Interlayers of Graphene Oxide for Neuromorphic Computing

por Wang, Li-Wen, Huang, Chih-Wei, Lee, Ke-Jing, Chu, Sheng-Yuan, Wang, Yeong-Her
Publicado 2023

Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction

por Suryono, Suryono, Rohman, Mohammad Saifur, Widjajanto, Edi, Prayitnaningsih, Seskoati, Wihastuti, Titin Andri, Oktaviono, Yudi Her
Publicado 2023

(Benzophenone imine-κN)­chlorido(hydrido­tripyrazolyl­borato)­(triphenyl­phosphine)ruthenium(II) diethyl ether solvate

por Tong, Hung-Chun, Hsu, Chih-Yung Chen, Lo, Yih-Hsing, Lin, Chia-Her, Wang, Yu
Publicado 2008

Bis(4,4′-methyl­enedicyclo­hexyl­aminium) μ-benzene-1,4-dicarboxyl­ato-bis­[tri­chlorido­zinc(II)] tetra­hydrate

por Hsu, Chen-Yen, Yeh, Chun-Wei, Wu, Chi-Phi, Lin, Chia-Her, Chen, Jhy-Der
Publicado 2008

(Dithio­benzoato-κ(2) S,S′)[hydridotris(pyrazol-1-yl-κN (2))borato](triphenyl­phosphine-κP)ruthenium(II)

por Lin, Chia-Her, Liang, Yao-Ren, Tong, Hung-Chun, Lo, Yih Hsing, Kuo, Ting Shen
Publicado 2008

Methyl­ene bis­(dithio­benzoate)

por Liang, Yao-Ren, Tong, Hung-Chun, Lo, Yih-Hsing, Lin, Chia-Her, Kuo, Ting Shen
Publicado 2008

(Benzonitrile-κN)chlorido[hydrido­tris(pyrazol-1-yl-κN (2))borato](triphenyl­phosphine-κP)ruthenium(II) ethanol solvate

por Tong, Hung-Chun, Hung, Yu-Chen, Wang, Po-Yo, Lin, Chia-Her, Lo, Yih-Hsing
Publicado 2009